Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole

Thomas O Kovacs, James W Freston, Marian M Haber, Stuart Atkinson, Barbara Hunt, David A Peura, Thomas O Kovacs, James W Freston, Marian M Haber, Stuart Atkinson, Barbara Hunt, David A Peura

Abstract

Background: Gastroesophageal reflux disease (GERD) is a chronic symptomatic condition and may be associated with erosive esophagitis (EE). Considerable data on the long-term maintenance of healing of EE are available, but data on long-term GERD symptom prevention and patient quality of life (QOL) are limited.

Aims: To investigate QOL in subjects with healed EE who received 12 months of double-blind maintenance treatment with lansoprazole or ranitidine, followed by long-term open-label lansoprazole therapy to prevent recurrence of EE.

Methods: Subjects with healed EE received 12 months of double-blind maintenance treatment with lansoprazole 15 mg once daily or ranitidine 150 mg twice daily, followed by dose-titrated, open-label lansoprazole therapy for up to 82 months.

Results: During double-blind treatment (n = 206), lansoprazole-treated patients showed significantly (P <or= 0.05) greater improvements than ranitidine-treated patients in the frequency, severity, and 'bothersomeness' of heartburn, the symptom index, problems of activity limitation, eating and drinking problems, symptom problems, health distress, and social functioning. During dose-titrated, open-label treatment (n = 195), all disease-specific QOL scales except sleep improved significantly (P < 0.001) from open-label baseline at each time-point.

Conclusions: Maintenance treatment with lansoprazole for 12 months in healed EE subjects produced significantly greater improvements in QOL indicators than ranitidine. These improvements were sustained during dose-titrated, open-label lansoprazole treatment.

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Change in severity and frequency of heartburn during the double-blind maintenance period. A positive change indicates improvement

References

    1. Shaw MJ, Crawley JA. Improving health-related quality of life in gastro-oesophageal reflux disease. Drugs. 2003;63:2307–2316. doi: 10.2165/00003495-200363210-00003.
    1. DeVault KR, Castell DO, American College of Gastroenterology Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190–200. doi: 10.1111/j.1572-0241.2005.41217.x.
    1. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903–912.
    1. Kamolz T, Pointner R, Velanovich V. The impact of gastroesophageal reflux disease on quality of life. Surg Endosc. 2003;17:1193–1199. doi: 10.1007/s00464-002-9229-4.
    1. Peura Da, Freston JW, Haber MM, Kovacs TO, Hunt B, Atkinson S. Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. Dig Dis Sci. 2009;54:955–963. doi: 10.1007/s10620-008-0466-9.
    1. Kovacs TO, Freston JW, Haber MM, et al. Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. Dig Dis Sci. 2009 [Epub ahead of print].
    1. Stewart AL, Ware JE Jr, editors. Measuring functioning and well-being. The Medical Outcomes Study approach. Durham, North Carolina: Duke University Press; 1992.
    1. Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305:160–164. doi: 10.1136/bmj.305.6846.160.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36®). I. Conceptual framework and item selection. Med Care. 1992;30:473–483. doi: 10.1097/00005650-199206000-00002.
    1. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36®): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–263. doi: 10.1097/00005650-199303000-00006.
    1. Fazio AF. A concurrent validational study of the NCHS General Well-Being Schedule. Vital Health Stat 2. 1977;(73):1–53.
    1. Rush DR, Stelmach WJ, Young TL, Kirchdoerfer LJ, Scott-Lennox J, Holverson HE, Sabesin SM, Nicholas TA. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract. 1995;41(2):126–136.
    1. Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract. 1996;50:190–194.
    1. Earnest D, Robinson M, Rodriguez-Stanley S, Ciociola AA, Jaffe P, Silver MT, Kleoudis CS, Murdock RH. Managing heartburn at the ‘base’ of the GERD ‘iceberg’: effervescent ranitidine 150 mg b.d. provides faster and better heartburn relief than antacids. Aliment Pharmacol Ther. 2000;14:911–918. doi: 10.1046/j.1365-2036.2000.00785.x.
    1. Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis. 1998;16:284–291. doi: 10.1159/000016878.
    1. Wiklund I, Bardhan KD, Müller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, Scott M, Weir D, Fulton C, Gillon K, Peacock R. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital J Gastroenterol Hepatol. 1998;30:19–27.
    1. Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N, ROSE Trial Investigators Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand J Gastroenterol. 2006;41:1132–1140. doi: 10.1080/00365520600615781.
    1. Pace F, Negrini C, Wiklund I, Rossi C, Savarino V, The Italian ONE Investigators Study Group Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349–356. doi: 10.1111/j.1365-2036.2005.02558.x.
    1. Ciovica R, Gadenstätter M, Klingler A, Lechner W, Riedl O, Schwab GP. Quality of life in GERD patients: medical treatment versus antireflux surgery. J Gastrointest Surg. 2006;10:934–939. doi: 10.1016/j.gassur.2006.04.001.
    1. Hansen AN, Bergheim R, Fagertun H, Lund H, Wiklund I, Moum B. Long-term management of patients with symptoms of gastro-oesophageal reflux disease—a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practitioners setting. Int J Clin Pract. 2006;60:15–22. doi: 10.1111/j.1368-5031.2006.00768.x.
    1. Kaplan-Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000;9:624–630. doi: 10.1001/archfami.9.7.624.
    1. Mathias SD, Castell DO, Elkin EP, Matosian ML. Health-related quality of life of patients with acute erosive reflux esophagitis. Dig Dis Sci. 1996;41:2123–2129. doi: 10.1007/BF02071390.
    1. Mathias SD, Colwell HH, Miller DP, Pasta DJ, Henning JM, Ofman JJ. Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci. 2001;46:2416–2423. doi: 10.1023/A:1012363501101.
    1. Colwell HH, Mathias SD, Pasta DJ, Henning JM, Hunt RH. Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. Dig Dis Sci. 1999;44:1376–1383. doi: 10.1023/A:1026647701477.
    1. Velanovich V. Quality of life and severity of symptoms in gastro-oesophageal reflux disease: a clinical review. Eur J Surg. 2000;166:516–525. doi: 10.1080/110241500750008565.
    1. Metz DC. Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med. 2004;117(Suppl 5A):49S–55S.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera